No convincing evidence prompts NICE no to Celgene's Revlimid
This article was originally published in Scrip
Celgene has, for now, failed to convince NICE, the health technology appraisal body for England and Wales to recommend its Revlimid (lenalidomide) for patients with myelodysplastic syndromes. Although it acknowledged the drug's benefits, like reduced time in hospital and need for transfusions, the institute was unconvinced that the drug actually extends lives.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.